Category: Federal Forum Posters
Purpose: Heart failure with reduced ejection fraction is a prevalent disease and public health problem associated with high morbidity and mortality rates, as well as significant costs. There are pharmacological therapies that exist for HFrEF which have been proven to reduce morbidity and mortality. The purpose of this project is to determine the utilization of mortality benefit medications in veterans with HFrEF at VA Maine.
Methods: A sample of patients selected from the Department of Veterans Affairs Ambulatory-Care-Sensitive Conditions (ACSC) Heart Failure Monitor dashboard will be selected for chart review. Chart reviews will identify HFrEF medication trials (including dosages) and fill history for an adherence assessment. Specifically, use of evidence-based beta-blockers (metoprolol succinate, carvedilol, bisoprolol), angiotensin converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARB), and the neprilysin inhibitor/angiotensin receptor blocker (sacubitril/valsartan) will be assessed. If a veteran is not on recommended therapy, the documented reason, if present, will be recorded. If there is no documented reason as to why a patient is not on evidence-based pharmacological therapy, a recommendation will be made to the veteran’s provider(s) in the form of a progress note in the computerized patient record system (CPRS). The data will then be analyzed to determine prevalence of veterans on appropriate mortality benefit pharmacological therapies.
Results: not applicable
Conclusion: not applicable
Morgan Harper– PGY1 Pharmacy Resident, VA Maine Healthcare System, Augusta, ME